A Phase 2 interventional study of rituximab and cyclophosphamide in Relapsed Follicular Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 43 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-04-29.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 194 studies testing rituximab in Lymphoma, Follicular — 12 open to participants now, 24 under way, 6 of them phase 3. Rituximab · Lymphoma, Follicular.
Among the 194 studies testing rituximab in Lymphoma, Follicular, this one is the 82nd largest by enrollment of the 188 interventional ones that give a count, is one of 15 that started in 2008, is one of 104 in phase 2, and was the 97th registered.
1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
Browse Lymphoma, Follicular studies →12 of the 194 studies testing rituximab in Lymphoma, Follicular are open now, in 12 countries. Recruiting first, the newest first:
University of Washington · Sites in United States
Ages 18+
Paolo Caimi, MD · Sites in United States
Ages 18+
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–75
Masonic Cancer Center, University of Minnesota · Sites in United States
Ages 18+
Reid Merryman, MD · Sites in United States
Ages 18+
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
194 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 50 · Phase 2 129 · Phase 3 37
First in 1997; this study’s year is marked. 15 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 55 is above the median of 48 across 1,503 interventional studies indexed under Lymphoma, Follicular.
Median enrollment 48 across the 188 interventional studies. Of the 150 that completed or were terminated, 75 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 194 have an industry lead sponsor. The 10 most frequent:
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
Takeda has 8 studies filed under Lymphoma, Follicular — fewer than ten, so there is no comparison to draw.
5 of the studies testing rituximab in Lymphoma, Follicular that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04224493Phase 3Epizyme, Inc.A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. | 2027-02-13 |
| NCT01479842Kami Maddocks, MDRituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | 2026-12-01 |
| NCT06471738Chinese PLA General HospitalCombination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma | 2026-12-30 |
| NCT01473628M.D. Anderson Cancer CenterRadiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma | 2027-05-20 |
| NCT04998669Juan P. Alderuccio, MDLoncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma | 2027-08-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 194 studies testing rituximab in Lymphoma, Follicular, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 2, two-arm, non-randomized, open-label, multicenter study evaluating the safety and efficacy of 2 VELCADE-containing regimens. Patients will be treated with either a combination of VELCADE, rituximab, cyclophosphamide, doxorubicin, and prednisone (VELCADE-R-CAP) or a combination of VELCADE, rituximab, cyclophosphamide, and prednisone (VELCADE-R-CP) based on investigator preference. Following completion of the treatment period, patients will receive maintenance therapy with rituximab up to a maximum of 2 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Received any of the following treatments or procedures outside of the specified timeframes:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
VELCADE will be administered as a 3- to 5-second intravenous bolus injection, rituximab 375 mg/m2 Intravenous on Day 1, cyclophosphamide 750 mg/m2 intravenous on Day 1, doxorubicin 50 mg/m2 intravenous on Day 1, VELCADE 1.6 mg/m2 intravenous on Days 1 and 8, prednisone 100 mg orally on Days 1 to 5 of a 21-day (3-week) cycle for 6 cycles.
Drug: rituximab · Drug: cyclophosphamide · Drug: doxorubicin · Drug: VELCADE · Drug: prednisone
VELCADE will be administered as a 3- to 5-second intravenous bolus injection, rituximab 375 mg/m2 intravenous on Day 1, cyclophosphamide 1000 mg/m2 intravenous on Day 1, VELCADE 1.6 mg/m2 intravenous on Days 1 and 8, prednisone 100 mg orally on Days 1 to 5 of a 21-day (3-week) cycle for 6 cycles.
Drug: rituximab · Drug: cyclophosphamide · Drug: VELCADE · Drug: prednisone
Number of Patients With Complete Response (CR)
Disappearance of all evidence of disease assessed by computed tomography (CT) and PET (position-emission tomography) according to the revised International Working Group (IWG) Criteria.
Time frame: 30 weeks
Number of Participants With Overall Response (OR)
OR = Complete Response (CR) + Partial Response (PR)according to the revised International Working Group (IWG) Criteria. CR is the disappearance of all evidence of disease assessed by CT and PET. PR is the regression of measurable disease and no new sites assessed by CT and PET.
Time frame: 30 weeks
Percentage of Participants With Progression-free Survival (PFS) at 1 Year
PFS was defined as the time from the first dose to the date of progressive disease (PD)/relapse or death, whichever comes first. For a participant who had not progressed/relapsed or died, PFS was censored at the last response assessment that was stable disease (failure to attain complete response/partial response or PD or better).
Time frame: Assessed at at the end of Cycle 2, at end of treatment visit, and every 12± 1 weeks for the first year (4 visits) until PD
Duration of Response
Time (in months) from the first documentation of a response (CR or partial response \[PR\]) to the date of first documentation of progressive disease or relapse from complete response. CR is defined as disappearance of all evidence of disease assessed by CT or PET; PR is defined as regression of measurable disease and no new sites assessed by CT or PET according to the revised International Working Group (IWG) Criteria.
Time frame: 2 years
Number of Patients Who Experienced at Least One Serious Adverse Event
Time frame: From completion of informed consent through 30 days after the last dose of study drug
| Milestone | VELCADE R-CAP | VELCADE R-CP |
|---|---|---|
| Started | 7 | 48 |
| Completed | 6 | 39 |
| Not completed | 1 | 9 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Adverse event | 0 | 6 |
| Withdrew: Lack of efficacy | 0 | 2 |
Disappearance of all evidence of disease assessed by computed tomography (CT) and PET (position-emission tomography) according to the revised International Working Group (IWG) Criteria.
| participants | VELCADE R-CAP | VELCADE R-CP |
|---|---|---|
| Number of Patients With Complete Response (CR) | 1 (0 to 36) | 13 |
OR = Complete Response (CR) + Partial Response (PR)according to the revised International Working Group (IWG) Criteria. CR is the disappearance of all evidence of disease assessed by CT and PET. PR is the regression of measurable disease and no new sites assessed by CT and PET.
| participants | VELCADE R-CAP | VELCADE R-CP |
|---|---|---|
| Number of Participants With Overall Response (OR) | 6 | 37 |
PFS was defined as the time from the first dose to the date of progressive disease (PD)/relapse or death, whichever comes first. For a participant who had not progressed/relapsed or died, PFS was censored at the last response assessment that was stable disease (failure to attain complete response/partial response or PD or better).
| percentage of participants | VELCADE R-CAP | VELCADE R-CP |
|---|---|---|
| Percentage of Participants With Progression-free Survival (PFS) at 1 Year | 67 (9.4 to —) | 63 (11.2 to —) |
Time (in months) from the first documentation of a response (CR or partial response \[PR\]) to the date of first documentation of progressive disease or relapse from complete response. CR is defined as disappearance of all evidence of disease assessed by CT or PET; PR is defined as regression of measurable disease and no new sites assessed by CT or PET according to the revised International Working Group (IWG) Criteria.
| Months | VELCADE R-CAP | VELCADE R-CP |
|---|---|---|
| Duration of Response | — | 21.9 (9.4 to NA) |
| participants | VELCADE R-CAP | VELCADE R-CP |
|---|---|---|
| Number of Patients Who Experienced at Least One Serious Adverse Event | 2 | 12 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VELCADE R-CAP | — | 2/7 (28.6%) | 7/7 (100%) |
| VELCADE R-CP | — | 12/48 (25%) | 47/48 (97.9%) |
| Event | VELCADE R-CAP | VELCADE R-CP |
|---|---|---|
| Neutropenic sepsisInfections and infestations | 1/7 | 0/48 |
| Oropharyngeal candidiasisInfections and infestations | 1/7 | 0/48 |
| PyrexiaGeneral disorders | 1/7 | 3/48 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/7 | 1/48 |
| Leukopenia NOSBlood and lymphatic system disorders | 1/7 | 0/48 |
| LymphadenopathyBlood and lymphatic system disorders | 0/7 | 2/48 |
| Blood culture positiveInvestigations | 0/7 | 2/48 |
| Bronchitis NOSInfections and infestations | 0/7 | 1/48 |
| Bronchitis acute NOSInfections and infestations | 0/7 | 1/48 |
| Pneumonia NOSInfections and infestations | 0/7 | 1/48 |
| Event | VELCADE R-CAP | VELCADE R-CP |
|---|---|---|
| AlopeciaSkin and subcutaneous tissue disorders | 4/7 | 8/48 |
| RigorsGeneral disorders | 4/7 | 6/48 |
| DysgeusiaNervous system disorders | 4/7 | 1/48 |
| DiarrhoeaGastrointestinal disorders | 2/7 | 24/48 |
| NauseaGastrointestinal disorders | 3/7 | 21/48 |
| ConstipationGastrointestinal disorders | 3/7 | 10/48 |
| StomatitisGastrointestinal disorders | 3/7 | 2/48 |
| DehydrationMetabolism and nutrition disorders | 3/7 | 3/48 |
| AnaemiaBlood and lymphatic system disorders | 3/7 | 8/48 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/7 | 6/48 |
| Age, Categorical(Participants) | VELCADE R-CAP | VELCADE R-CP | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 7 | 27 | 34 |
| >=65 years | 0 | 21 | 21 |
| Age Continuous(years) | VELCADE R-CAP | VELCADE R-CP | Total |
|---|---|---|---|
| Mean | 62.9 ± 8.30 | 62.3 ± 11.39 | 62.3 ± 10.98 |
| Sex: Female, Male(Participants) | VELCADE R-CAP | VELCADE R-CP | Total |
|---|---|---|---|
| Female | 5 | 24 | 29 |
| Male | 2 | 24 | 26 |
| Region of Enrollment(participants) | VELCADE R-CAP | VELCADE R-CP | Total |
|---|---|---|---|
| United States | 7 | 48 | 55 |
The record gives a start of Sep 2008, a primary completion of Feb 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2013, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rituximab · Cyclophosphamide · Bortezomib · Prednisone
Millennium Pharmaceuticals, Inc. →